Table: Astellas -9-MTH group results (IFRS)

Astellas Pharma

04/02/2026 06:31

Feb 4 (Reuters)- 
              Astellas Pharma Inc. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended       Year to 
                  Dec 31, 2025        Dec 31, 2024     Mar 31, 2026 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales             1.60 trln           1.45 trln        2.10 trln  
                   (+10.2 pct)         (+22.2 pct)      (+9.8 pct)  
  Operating          333.88            loss 22.48         340.00    
                                                       (+728.5 pct) 
  Pretax             328.56            loss 29.32         330.00    
                                                       (+956.5 pct) 
  Net                248.01            loss 24.15         250.00    
                                                       (+392.6 pct) 
  EPS Basic        138.48 yen        loss 13.49 yen     139.58 yen  
  EPS Diluted      138.02 yen        loss 13.49 yen                 
  Ann Div                               74.00 yen        78.00 yen  
  -Q2 Div           39.00 yen           37.00 yen                   
  -Q4 Div                               37.00 yen        39.00 yen  
 
  NOTE - Astellas Pharma Inc.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4503.T